Schwab Intermediate Term US Treasury ETF (09SL)

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen.  Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

Im glad I held my shares past $0.15

And don’t forget your buddy, AF. … .. . 

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

Have at it Brazen! ;)  … .. . :) 

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

https://x.com/thommic/status/2072760144774005081

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo

Good to know because I was thinking about letting it go but now I have a reason to hold

This is by far the Best piece Gary has written imho

https://garywallach.substack.com/p/from-qualification-to-harvest-could?r=3iu9hl&utm_campaign=post&utm_medium=web&triedRedirect=true

I doubt you will agree or bother reading what I have said but at least it wasn’t written by some AI.
I have read it all and you are right... I don't agree with ANY of it.

No, I don't believe they have done EVERYTHING right... But I do believe that had it been any other CEO...

Stay away stay very far away........

I’m busy today, but these results are in line with what I expected. Excellent, and very helpful for all current and potential stakeholders. Great for patients! For current therapy as well as future improvements with combination therapy. Happy 4th Tomorrow! (Top notch for valuation)

Ok, This Explains it. I didn't know which Wall St (Or elsewhere in Europe like James St) Scoundrel "Creditors' were "Filing TWICE or even More' to get their Money from multiple Lehman Entities ..Frankly, those SCUM should be prosecuted for Fraud and Thrown in Jail for Good...

They didn't go to Europe. They're already there. It's an Italian company! Y90 has no shelf life. To do a trial outside of manufacturing continent is a complete waste of time, as RDGL has well demonstrated already. One company has competent leadership and one doesn't. One company is over 4 year

What're you waiting for ?......

Drink

https://investorshub.advfn.com/uimage/uploads/2026/7/3/eg[hqgutsi_group_for_health_logo.jpg

.

I believe it was published by a standard member, right after the microcap club conference in June. I'm hoping that will help get a lot more eyes on it.

flipper44,

Thanks for explaining this. Just to be clear for others, you are describing OS as an absolute number (can’t change) from the data in the trial. The comparator number is what can change based on the methods utilized to measure SOC/placebo benefit. This difference in measu

The interesting thing was the companies that thought Elite was too big for them to purchase. Makes me think that the acceptable sale price is significantly higher than where we are now. I’d like to know the number they have in mind.

The Scam is getting called out by alot of the bagholders now, eh? PUMP and DUMP city is where your at. The Path is south. Typical OTC lies and rumors. SUB 12 and that's being very nice!